MAIA Reports 88% Disease Control with Ateganosine in NSCLC

Share on Social Media

MAIA Biotechnology's investigational ateganosine in Phase 2 THIO-101 study showing 88% disease control in advanced non-small cell lung cancer.
Image: Pixels

MAIA Biotechnology reports an 88% disease control rate in 43 patients in its expanded Phase 2 THIO-101 study of ateganosine for advanced NSCLC.

Written By: Mayuri Vaja, PharmD

Reviewed By: Pharmacally Editorial Team

MAIA Biotechnology has reported updated interim efficacy findings from Part C of its Phase 2 THIO-101 expansion study evaluating ateganosine (THIO) as a third-line treatment for advanced non-small cell lung cancer (NSCLC). The combined analysis of Parts A, B and C demonstrated an 88% disease control rate (DCR), with disease control observed in 38 of 43 efficacy-evaluable patients who had progressed following previous immunotherapy and chemotherapy. The findings provide an updated assessment of the investigational telomere-targeting therapy as the company advances its clinical development programme.

Expanded Phase 2 Study Shows Consistent Disease Control

THIO-101 is evaluating ateganosine in patients with advanced NSCLC who did not respond to, or developed resistance and progressed following, previous immune checkpoint inhibitor therapy and chemotherapy.

As of October 1, 2026, the combined efficacy-evaluable population across Parts A, B and C included 43 third-line NSCLC patients who had undergone at least one tumour assessment after initiating treatment. Disease control, defined as stable disease or better, was observed in 38 patients, representing an overall DCR of 88%.

According to MAIA, this compares with reported disease control rates of approximately 25%–35% associated with standard third-line chemotherapy regimens. However, this comparison is based on historical data rather than a direct comparative analysis.

The company also reported that patients across the study parts consistently demonstrated stable disease or better at their first tumour assessment following treatment initiation. The updated Part C findings were aligned with earlier observations from Parts A and B, extending the reported efficacy signal to a larger pooled patient population.

The 88% DCR represents an interim pooled analysis and does not establish an improvement in overall survival or superiority over existing treatments.

Sequential Treatment with Ateganosine and Cemiplimab

In THIO-101, patients receive ateganosine at a reported dose of 180 mg followed by cemiplimab (Libtayo), a programmed cell death protein 1 (PD-1) inhibitor, in 21-day treatment cycles.

The sequential treatment strategy is designed to enhance and prolong antitumour immune responses. Ateganosine is intended to act as both an anticancer agent and an immune-priming compound before PD-(L)1 inhibition.

THIO-101 is a multicentre, open-label, dose-finding Phase 2 clinical trial evaluating different ateganosine doses in combination with cemiplimab. Its primary objectives include assessing safety and tolerability and evaluating clinical activity, with overall response rate (ORR) identified as the primary clinical efficacy endpoint. The expansion programme specifically assesses third-line treatment in patients with resistance to previous checkpoint inhibitor therapy and chemotherapy.

Although the latest announcement provides the pooled DCR, it does not disclose updated ORR, progression-free survival or overall survival results for this analysis.

Mechanism of Action: Targeting Cancer Cell Telomeres

Ateganosine, also known as THIO, 6-thio-dG or 6-thio-2′-deoxyguanosine, is a first-in-class investigational telomere-targeting agent.

Telomeres and the enzyme telomerase play important roles in cancer cell survival and resistance to treatment. Ateganosine is designed to induce telomerase-dependent modification of telomeric DNA, triggering DNA damage responses and selective cancer cell death.

The resulting damaged telomeric fragments accumulate in cytosolic micronuclei and activate innate immune pathways, including cGAS/STING, alongside adaptive T-cell responses. In preclinical cancer models, sequential administration of ateganosine followed by PD-(L)1 inhibitors produced sustained tumour regression and cancer-specific immune memory. These findings provide the biological rationale for its clinical evaluation but have not established the same effects in patients.

Phase 3 Development and Regulatory Outlook

MAIA has completed enrolment in Part C of the Phase 2 THIO-101 expansion study, which included clinical sites across Hungary, Poland, Turkey, Georgia, Romania, Taiwan and the United States.

Meanwhile, the company is advancing THIO-104, an ongoing pivotal Phase 3 trial evaluating third-line ateganosine in a patient population similar to that of THIO-101 Part C. The study is progressing towards regulatory milestones, including an interim overall survival analysis expected in 2027.

Ateganosine is also being developed under the US Food and Drug Administration’s (FDA) Fast Track designation. MAIA stated that additional data from THIO-101 Part C may support a potential accelerated approval filing with the FDA.

The expanded Phase 2 findings provide further evidence of disease control in previously treated advanced NSCLC. However, the relatively small efficacy-evaluable population and absence of updated survival outcomes limit conclusions about the treatment’s clinical benefit. Results from the ongoing Phase 3 programme will be important in determining whether the observed efficacy translates into meaningful patient benefit and supports future regulatory submissions.

References

MAIA Biotechnology Reports Consistent Strong Efficacy in Expanded Phase 2 THIO-101 Study in Non-Small Cell Lung Cancer, MAIA Biotechnology, November 17, 2026.

THIO Sequenced with Cemiplimab in Advanced NSCLC, ClinicalTrials.gov ID NCT05208944

About the Writer

Mayuri Vaja (Linkedin) is a Pharm.D professional with a strong interest in clinical research, pharmacovigilance, and medical writing, supported by certifications in pharmacovigilance and academic projects exploring AI in healthcare and drug safety.
With a growing focus on evidence-based healthcare and scientific communication, she is developing expertise in clinical research and translating healthcare evidence into clear, meaningful content.
As a Pharmacally healthcare writer, Mayuri is committed to creating accurate, research-driven, and clinically relevant healthcare content while continuously strengthening her professional skills.


Share on Social Media
Scroll to Top